incidence and epidemiology

An estimated 1.6 million new lung cancers are diagnosed worldwide each year. The highest incidence rates in males are observed in Central/Eastern and Southern Europe (37 and 49 per 100 000, respectively), whereas in women the highest rates are found in Northern Europe (36 per 100 000) [1]. Five-year survival rates of lung cancer patients have only slightly improved during the past decade but remain low at 10% [2].

Small-cell lung cancer (SCLC) originates from neuroendocrine-cell precursors and is characterised by its rapid growth, its high response rates to both chemotherapy and radiotherapy and development of treatment resistance in patients with metastatic disease. In the Western world, the proportion of patients with SCLC has decreased to 13% [3]. Virtually all patients have a history of tobacco use. Therefore, smoking habits are closely linked to incidence, which varies across different populations. In addition, the new description of large-cell neuroendocrine tumours in the 1990s, which may have been summarised previously as SCLC, possibly has contributed to the decline. Smoking cessation not only reduces the risk of developing SCLC but also has been shown to decrease the risk of death of patients with localised SCLC by almost 50% [4]. Only one-third of the patients are diagnosed with localised disease, where cure is the treatment goal. Due to the aggressive natural course, screening by radiological imaging is unlikely to lead to a reduction of mortality, and smoking prevention will undoubtedly remain the primary and most important intervention to further decrease mortality [5].

diagnosis and pathology/molecular biology

Pathological diagnosis should be made according to the World Health Organisation (WHO) classification using morphology (uniform round to spindled-shaped small cells, sparse cytoplasm, high mitotic index, necrotic areas). Immunohistochemistry to confirm the diagnosis of SCLC (synaptophysin, chromogranin A, CD56, thyroid transcription factor 1 and MIB-1) is not mandatory, but should be used in case of any doubt (e.g. in case of pronounced crush artefacts). Due to its frequent central localisation within the chest, biopsies may best be obtained by bronchoscopy. Other methods include mediastinoscopy, endobronchial ultrasound (EBUS), endoscopic ultrasound, transthoracic needle aspiration or even thoracoscopy if necessary. A biopsy from a metastatic lesion may be the preferred option if the location of the metastasis is easily and safely accessible to biopsy, as this will also pathologically stage the patient (e.g. liver, skin).

staging and risk assessment

The prognosis of SCLC strongly depends on the tumour stage. The new tumour-node-metastasis (TNM) version 7 staging system according to the Union for International Cancer Control (UICC) as adopted for non-small-cell lung cancer should also be used for SCLC [I, A] [6,7] (See Tables 1 and 2). This classification should replace the former 1989 International Association for the Study of Lung Cancer (IASLC) staging system, which defined limited stage as tumour being confined to one hemithorax with regional lymph node metastasis including both ipsilateral and contralateral hilar, supraclavicular and mediastinal nodes, as well as ipsilateral pleural effusion. The current TNM staging system is based on 8088 SCLC patients and provides better prognostic information and more precise nodal staging, which is required for conformal radiation techniques and intensity-modulated radiation therapy. The
Table 1. Tumour node metastasis classification.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Tumour extension</th>
<th>Node involvement</th>
<th>Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>Primary tumour</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1</td>
<td>≤3 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1a</td>
<td>≤2 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1b</td>
<td>&gt;2 to 3 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>Main bronchus ≥2 cm from carina invades visceral pleura, partial atelectasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2a</td>
<td>&gt;3–5 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T2b</td>
<td>&gt;5–7 cm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T3</td>
<td>&gt;7 cm; chest wall, diaphragm, pericardium, mediastinal pleura, main bronchus &lt;2 cm from carina, total atelectasis, separate nodule(s) in the same lobe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>T4</td>
<td>Mediastinum, heart, great vessels, carina, trachea, esophagus, vertebral; separate tumour nodule(s) in a different ipsilateral lobe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>Ipsilateral peribronchial, ipsilateral hilar</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N1</td>
<td>Subcarinal, ipsilateral mediastinal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N2</td>
<td>Contralateral mediastinal or hilar, scalene or supraclavicular</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N3</td>
<td>Distant metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M0</td>
<td>Occult carcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1</td>
<td>Separate tumour nodule(s) in a contralateral lobe; pleural nodules or malignant pleural, or pericardial effusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1a</td>
<td>Separate tumour nodule(s) in a contralateral lobe; pleural nodules or malignant pleural, or pericardial effusion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M1b</td>
<td>Distant metastasis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


Table 2. Tumour stage grouping.

<table>
<thead>
<tr>
<th>Stage</th>
<th>Occult carcinoma</th>
<th>TX</th>
<th>N0</th>
<th>M0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>T1a, b</td>
<td>N0</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IA</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IB</td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage II</td>
<td>T2a, b</td>
<td>N1</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T2a</td>
<td>N1</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2b</td>
<td>N1</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage III</td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1a, b, T2a, b</td>
<td>N2</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T4</td>
<td>N2</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td></td>
</tr>
</tbody>
</table>


Initial assessment should encompass medical history including smoking history, physical examination, complete blood count including differential count, liver enzymes, sodium, potassium, calcium, glucose, lactate dehydrogenase levels and renal function tests, and in the case of localised disease, lung function tests. An initial computed tomography (CT) scan with contrast of the chest and abdomen is recommended. If the metastatic stage is not obvious on the CT scan or clinical findings suggest bone or brain involvement, further imaging with bone scintigraphy and CT or magnetic resonance imaging (MRI) of the brain are recommended. In case of abnormal blood count or signs of blood–bone marrow barrier rupture (e.g. peripheral blood erythroblasts), a bone marrow aspiration and biopsy may be indicated, particularly in patients with otherwise absent metastases [V, C]. Alternatively to CT and bone scintigraphy, a 2-fluoro-2-deoxy-D-glucose positron-emission-tomography (FDG-PET) CT scan can be carried out. A recent review has suggested that with PET-CT 9% of the patients are up- and 4% downstaged [V, C]; however, individual studies in this analysis were non-randomised and were either retrospective or small and frequently lacked histological confirmation. Thus, PET-CT findings which could impact treatment decisions should be pathologically confirmed [III, C].

In patients with a solitary metastasis, its pathological confirmation should not delay treatment start. In this case, the solitary metastatic lesion’s size should be re-evaluated after two cycles, allowing further judgement as to whether it is a true metastatic site [V, C]. Alternatively, an initial second radiological method (e.g. MRI if solitary small liver or bone lesion) is recommended [V, C]. If a pleural or pericardial effusion is the only site of M1, no malignant cells are identified in the pleural fluid and a plausible explanation other than tumour involvement is clinically suspected, treatment should be according to an M0 status [V, B].

management of localised disease (t1-4, n0-3 m0)

In localised disease, median survival and 2-year survival rates have been reported to be 15–20 months and 20%–40% respectively [9]. Importantly, the proportion of patients who survive for 5 years has been reported to be 20%–25% [10].

Approximately 5% of patients with SCLC present as T1, 2 N0, 1 M0 tumours (Figure 1). These patients have more favourable outcomes with 5-year survival rates in the order of 50% [11, 12]. Most series report on patients having been treated with surgery for a coin lesion without pathological diagnosis. A surgical approach in this group of patients is justified after ruling out mediastinal lymph node involvement (i.e. negative lymph nodes on CT scan, PET-CT scan or EBUS and/or mediastinoscopy if enlarged) [V, C]. Postoperatively, four cycles of adjuvant chemotherapy should be administered [III, C]. In the case of unforeseen N2 or N1 or in patients who have not undergone systematic nodal dissection, postoperative radiotherapy should be considered [V, C]. There is no role for surgery after induction chemotherapy in N2 disease [II, B]. In the absence of randomised trials, due to frequent early dissemination and because total gross tumour volume has shown to be an

former term limited stage would now include T1-4, N0-3 M0 tumours, whereas metastatic tumours encompass former extensive stage patients. In addition, T1 or T2 N0 or N1 M0 tumours (previously described as ‘very limited stage’) were identified as a group with a more favourable outcome compared with patients with N2 or N3 disease.
independent prognostic factor leading to improved outcomes irrespective of the local treatment modality, patients with T1, 2 N0, 1 M0 may alternatively be treated with combined concurrent chemotherapy and thoracic radiotherapy [III, C] [13]. This treatment is recommended as the first option in patients who are at increased risk for perioperative complications (e.g. significant concomitant medical illnesses) [II, C]. All patients with T1, 2 N0, 1 M0 should be considered for prophylactic cranial irradiation (PCI) if they have responded to initial treatment using the same dose and fractionation as for patients with stage III SCLC.

All other patients with T1-4, N0-3 M0 tumours who are in a good performance status (PS) should be treated with concurrent chemotherapy and thoracic radiotherapy [I, A]. Several radiotherapy schedules have been studied. One phase III trial of 471 patients reported a superior 5-year overall survival (OS) with twice-daily radiotherapy (1.5 Gy twice-daily, 30 fractions) compared with once-daily (1.8 Gy, 25 fractions) of 26% versus 16% (P = 0.04) [10]. The inconvenience of the twice-daily administration and the significantly increased rate of transient grade 3 oesophagitis were, however, the main reasons why this regimen was not widely adopted. This current accelerated standard schedule is being compared with 70 Gy in daily fractions as an experimental arm in ongoing North American and European phase III trials in patients in which the lung dose can be kept within safe limits. Outside of a clinical trial, a twice-daily 1.5 Gy in 30-fraction regimen should be considered in fit patients who are willing to accept temporarily increased toxicity [I, B]. The chemotherapy schedule consists of four cycles of cisplatin–etoposide or 4–6 cycles if a once-daily radiotherapy schedule is used [I, B].

The optimal timing of the concurrent radiotherapy has been studied extensively. Seven older trials assessing the timing of thoracic radiotherapy were analysed in two meta-analyses, with the conclusion that thoracic radiotherapy should be initiated as early as possible beginning with the first or second cycle when cisplatin-based chemotherapy was used [14, 15]. In addition, an analysis of four of these studies which reported 5-year survival rates and used two concurrent arms with cisplatin–etoposide treatment found improved 5-year survival rates if the time between the first day of chemotherapy and the last day of radiotherapy was <30 days [hazard ratio (HR): 0.62, 95% confidence interval (CI) 0.49–0.80, P = 0.0003] [16]. An update of an American trial reached the same conclusion [17]. On the other hand, a recent randomised trial did not show any survival difference when radiotherapy was administered with the third as opposed to the first cycle with less toxicity in the late arm in an Asian population [18]. Starting chest radiotherapy within 30 days after the beginning of chemotherapy is preferred [II, B]. When the general condition of the patient does not allow for the immediate administration of concurrent treatment or lung constraints preclude the target radiotherapy dose, chest irradiation may be postponed until the start of the third cycle of chemotherapy [II, B].

The optimal target volume remains to be defined. Omission of elective node irradiation based on CT scans should be used with caution as this strategy may result in nodal failures [III, C]. Whether selective node irradiation based on pre-treatment PET-CT scans can replace elective node irradiation has been addressed in two small studies [19, 20]. Both studies, one prospective and the other one retrospective, have shown promisingly low nodal recurrence rates. This strategy, however, needs further prospective evaluation although it has been adopted already in some national guidelines [III, D]. Elective nodal volumes are not well-defined but may include the involved lymph node regions and one adjacent region and supraclavicular regions depending on the location of the primary tumour and the N2 or N3 nodes.

RESECT criteria are not well-suited to determine tumour response after radiotherapy. Patients in a reasonably good PS without progression should be offered PCI. The recommended dose is 25 Gy in 10 daily fractions [I, A]. Although PCI increases long-term survival, patients >65 years and/or with important vascular disease have a slightly elevated risk (HR 1.04) of developing neurocognitive side-effects [21, 22].

management of metastatic disease

first-line treatment

Treatment of stage IV SCLC is palliative, and combination chemotherapy has been the main treatment option for more

Figure 1. Small-cell lung cancer (SCLC) treatment algorithm.
than three decades. Despite response rates (RRs) close to 70%, outcomes remain poor with a median progression-free survival (PFS) of only 5.5 months and a median OS of <10 months [22, 23].

A meta-analysis of 19 randomised trials with a total of 4054 patients demonstrated prolonged OS of patients receiving a cisplatin-containing regimen compared with older chemotherapy combinations [25]. Another meta-analysis of 36 trials reported an OS benefit in favour of etoposide alone or in combination with cisplatin compared with regimens that did not contain one of the two drugs [26]. These results led to the adoption of etoposide–cisplatin as a standard treatment regimen. A recent individual patient data meta-analysis including four randomised clinical trials comparing cisplatin versus carboplatin-based combination chemotherapy demonstrated no difference in efficacy outcomes including RR, PFS and OS [24]. In the carboplatin group, increased haematological toxicity rates were observed, whereas higher renal and neurotoxicity was seen with cisplatin. According to these results, cisplatin can be substituted by carboplatin in patients with metastatic SCLC [I, B]. Due to the limited number of only 663 patients included in this analysis, there was limited statistical power to draw conclusions in important subgroups such as patients with localised disease and young patients. In these subgroups, etoposide–cisplatin is recommended [II, B].

Studies with 3-drug regimens and the administration of increased dose intensity regimens, using increased dose or non-cross-resistant regimens, have not consistently reported improvement in OS. In addition, they have frequently been associated with significant toxicity in this usually co-morbid patient population [27]. Such regimens are not recommended as first-line treatment [II, C].

A recent literature-based meta-analysis of seven randomised studies showed an improved OS, but not PFS with irinotecan–platinum compared with etoposide–platinum. Irinotecan led to more gastrointestinal toxic effects, while more haematological toxic effects were observed with etoposide [28]. The results, however, were primarily driven by Asian studies, and pharmacogenomic differences between Asian and Western populations possibly contributing to these differential outcomes have previously been described [29]. No chemotherapy doublet has yet been shown to be superior to i.v. etoposide–platinum in a Western population. Randomised phase III trials which compared irinotecan–cisplatin, gemcitabine–carboplatin (in poor prognostic patients only) or i.v. or oral topotecan–cisplatin to etoposide–platinum have demonstrated non-inferiority for survival [30–33]. These regimens are recommended as alternative treatment options in the case of contraindications to etoposide [II, C].

Continuation of chemotherapy beyond 4–6 cycles has been assessed in at least 14 randomised, controlled trials. Although a significant OS benefit was reported in a literature-based review including 11 trials (HR 0.89, 95% CI: 0.81–0.92; P = 0.02), the benefit was small and high heterogeneity among the included trials was observed [34]. Similarly, a previous meta-analysis found a small OS benefit of 4% at 2 years with maintenance therapy [35]. However, the majority of the randomised, controlled trials did not show any significant OS benefit, and a properly designed large clinical trial to address this question is lacking. In addition, there is a considerable risk of increased toxicity with prolonged platinum-based chemotherapy. Continuing chemotherapy beyond 4–6 cycles of first-line treatment is not recommended [II, B].

PCI significantly decreases the risk of symptomatic brain metastases (from 40.4% to 14.6% at 1 year) and increases OS (HR 0.68; 95% CI, 0.52–0.88) [36]. Of note, in this trial initial pre-treatment brain imaging was not required. PCI is associated with adverse effects such as fatigue and hair loss, and health-related quality of life may be negatively affected as well [37]. Patients with any response to first-line treatment and who have a reasonably good PS should be evaluated for PCI [II, B]. The PCI dose may be 25 Gy in 10 daily fractions or 20 Gy in 5 fractions.

Due to the often centrally located primary tumours, symptoms such as dyspnoea, infections due to atelectasis, chest pain or superior vena cava syndrome are frequent and make the incorporation of thoracic radiotherapy into the initial treatment algorithm an appealing concept. A four-arm randomised phase III trial has demonstrated a survival benefit of concurrent thoracic radiotherapy in patients whose primary tumours have responded after three cycles of cisplatin–etoposide and whose metastatic sites were in complete remission (OS: 17 versus 11 months, P = 0.041) [38]. This single centre trial was however small (54 patients per arm), and the concurrent chemoradiotherapy treatment used does not correspond to the current standard approach. The routine use of thoracic irradiation in patients with metastatic SCLC is not recommended and the results of the Dutch phase III trial (CREST study) testing this concept should be awaited [II, C].

**second-line treatment**

RRs to second-line treatment depend on the treatment-free interval and are usually in the order of 10% in resistant disease (i.e. progression-free interval <3 months) and 20% in sensitive disease (i.e. interval >3 months). In refractory patients (i.e. patients not responding or progressing during chemotherapy) and resistant patients with early relapse (<6 weeks), outcomes are poor and the clinical benefit of further systemic therapy is uncertain. For these patients, participation in a clinical trial or best supportive care is recommended [II, C]. Oral topotecan led to better symptom control including slower time to quality of life deterioration and improved survival compared with best supportive care in a study in which half of the patients had resistant disease [39]. Prior to topotecan development, anthracycline-based regimes have been commonly used, including cyclophosphamide, doxorubicin and vincristine (CAV). In 1999, a trial of i.v. topotecan and CAV demonstrated equal efficacy, with similar RRs, time-to-progression, and OS, and better tolerance when compared with CAV [40]. Oral and i.v. topotecan have shown to be equally effective [41], but with differing toxicity profiles. Either oral or i.v. topotecan are recommended for patients having resistant or sensitive relapse with CAV being an alternative option [II, B]. Only patients with sensitive disease derive benefit from rechallenge with first-line therapy (usually platinum–etoposide) [IV, C].

A recent randomised, phase III trial failed to show a survival benefit of amrubicin versus topotecan, despite a higher RR and...
Table 3. Summary of recommendations.

| Diagnosis | • Pathological diagnosis should be made according to the World Health Organisation (WHO) classification  
|          | • Biopsies are best obtained by bronchoscopy. A biopsy from a metastatic lesion is preferred if the location of the metastasis can be easily and safely accessed to biopsy (e.g. liver, skin)  
|          | • No predictive molecular marker for treatment selection is currently available  
|          | • Initial assessment should include smoking history, physical examination, complete blood count, liver enzymes, sodium, potassium, calcium, glucose, lactate dehydrogenase levels and lung (if localised disease) and renal function tests  
|          | • A computed tomography (CT) scan with contrast of the chest and abdomen is recommended  
|          | • In localised disease or if symptoms or clinical findings suggest involvement, additional bone scintigraphy and CT or MRI of the brain are recommended  
|          | • 2- fluor-2-desoxy-β-glucose positron-emission-tomography (FDG-PET CT) scan is optional in localised disease. PET findings, which modify treatment decisions, should be pathologically confirmed [III, C]  
|          | • A bone marrow aspiration and biopsy should be carried out in the case of abnormal blood counts suggesting involvement, particularly in localised disease [V, C]  
|          | • Version 7 of the TNM staging system according to the Union for International Cancer Control (UICC) should be used (Tables 1 and 2) [II, A]  
| Staging and risk assessment | • Figure 1 summarises the treatment algorithm of patients with SCLC  
|          | • In localised disease, a bimodality treatment approach is curative and chemotherapy plus radiotherapy result in 5-year survival rates of 20%–25%  
|          | • Treatment of stage IV SCLC is palliative and various combination chemotherapy regimens demonstrate similarly high response rates (RRs) of 60%–70%. Due to frequent rapid relapse and limited activity of second-line treatment, overall survival (OS) remains poor (<10 months)  
|          | • All SCLC patients responding to first-line treatment should be evaluated for prophylactic cranial irradiation (PCI)  
|          | • A small subset of patients who present with T1, 2 N0, 1 M0 tumours have a more favourable outcome and 5-year survival rates of 50% have been reported with surgery. These patients should receive four cycles of adjuvant chemotherapy [III, C] and postoperative thoracic radiotherapy if staged pN1 or pN2 [V, C]  
|          | • All other patients with T1-4, N0-3 M0 tumours who are in a good performance status (PS) should be treated with concurrent chemotherapy and thoracic radiotherapy [I, A]  
|          | • The best OS rates in fit patients were demonstrated with twice-daily 1.5 Gy in 30 fractions given concurrently with four cycles of cisplatin and etoposide [I, B]  
|          | • Patients who are not fit enough for twice-daily radiotherapy or are unwilling to accept increased toxic effects may be treated with a once-daily radiotherapy schedule with 4–6 cycles of concurrent etoposide–cisplatin [I, B]  
|          | • In good PS patients, thoracic radiotherapy should be initiated with the first or second cycle (i.e. within 30 days) of chemotherapy [II, B]  
|          | • All patients with T1-4, N0-3 M0 disease without disease progression after treatment and a reasonably good PS should be offered PCI [I, A]  
| Treatment strategy | • 4–6 cycles of etoposide plus cisplatin or carboplatin are recommended [I, B]  
|          | • In young patients and patients with localised disease, etoposide–cisplatin is recommended [II, B]  
|          | • Irinotecan–cisplatin, gemcitabine–carboplatin (in poor prognostic patients only) and i.v. or oral topotecan–cisplatin are alternative options if etoposide is contraindicated [II, C]  
|          | • Patients in a reasonably good PS with any response to first-line treatment should be evaluated for PCI [II, B]  
|          | • The routine use of thoracic irradiation in patients with metastatic SCLC is not recommended [II, C]  
|          | • For refractory patients and resistant patients with early relapse (<6 weeks), participation in a clinical trial or best supportive care is recommended [II, C]  
|          | • Oral or i.v. topotecan are recommended for patients having resistant or sensitive relapse with CAV being an alternative option [II, B]  
|          | • Patients with sensitive relapse may derive benefit from reintroduction of the first-line regimen (usually platinum–etoposide) [V, C]  
|          | • The occurrence of second malignancies, particularly if smoking is continued, is of concern in survivors and smoking cessation counselling is essential  
|          | • Two to three-monthly CT scans are recommended in patients with metastatic disease potentially qualifying for further treatments [V, C]  
|          | • Six-monthly CT scans for 2 years with lengthening of intervals thereafter are recommended for patients with non-metastatic disease who have received potentially curative treatment [V, C]  
| Treatment of localised disease | • 6 cycles of concurrent etoposide–cisplatin (in poor prognostic patients only) and i.v. or oral topotecan–cisplatin are recommended [II, B]  
| First-line treatment of | • In young patients and patients with localised disease, etoposide–cisplatin is recommended [II, B]  
| metastatic disease | • Irinotecan–cisplatin, gemcitabine–carboplatin (in poor prognostic patients only) and i.v. or oral topotecan–cisplatin are alternative options if etoposide is contraindicated [II, C]  
|          | • Patients in a reasonably good PS with any response to first-line treatment should be evaluated for PCI [II, B]  
| Second-line treatment of | • The routine use of thoracic irradiation in patients with metastatic SCLC is not recommended [II, C]  
| metastatic disease | • For refractory patients and resistant patients with early relapse (<6 weeks), participation in a clinical trial or best supportive care is recommended [II, C]  
|          | • Oral or i.v. topotecan are recommended for patients having resistant or sensitive relapse with CAV being an alternative option [II, B]  
|          | • Patients with sensitive relapse may derive benefit from reintroduction of the first-line regimen (usually platinum–etoposide) [V, C]  
| Follow-up and long-term | • The occurrence of second malignancies, particularly if smoking is continued, is of concern in survivors and smoking cessation counselling is essential  
| implications | • Two to three-monthly CT scans are recommended in patients with metastatic disease potentially qualifying for further treatments [V, C]  
|          | • Six-monthly CT scans for 2 years with lengthening of intervals thereafter are recommended for patients with non-metastatic disease who have received potentially curative treatment [V, C]
improved quality of life with amrubicin [42]. The subgroup of refractory patients derived a small survival benefit from amrubicin. Amrubicin is currently not available in Western countries.

personalised medicine

In this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine.

follow-up and long-term implications

All patients with metastatic SCLC and approximately three-quarters of patients with localised disease will progress. In survivors, the occurrence of second malignancies, particularly if smoking is continued, is of concern and smoking cessation counselling is essential. The main goal of regular follow-up is to detect recurrence early, while the patient is still in a good PS [43]. The frequency of follow-up visits depends on the availability of treatment options. Although there is no clinical trial evaluating the benefit of regular follow-up, 2–3-monthly CT scans are recommended in patients with metastatic disease potentially qualifying for further treatments. Patients with localised disease who have received potentially curative treatment should undergo 3–6-monthly CT scans for two years with lengthening of intervals thereafter. Due to the high risk of secondary primary lung cancer, annual low-dose CT scans after 5 years might be considered [V, C]. Summary of recommendations is provided in Table 3.

note

Levels of evidence and grades of recommendation have been applied using the system shown in Table 4. Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.

Table 4. LOE and GOR adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System†

<table>
<thead>
<tr>
<th>Levels of evidence</th>
<th>Grades of recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
<tr>
<td>II</td>
<td>Moderate evidence against efficacy or for adverse outcome, generally not recommended</td>
</tr>
<tr>
<td>III</td>
<td>Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional</td>
</tr>
<tr>
<td>IV</td>
<td>Strong evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, ...), optional</td>
</tr>
<tr>
<td>V</td>
<td>Strong evidence for efficacy with a substantial clinical benefit, strongly recommended</td>
</tr>
</tbody>
</table>


conflict of interest

Dr Peters has reported consultancy/honoraria from Roche, Eli Lilly, AstraZeneca, Pfizer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo, and Tesaro. Dr Felip has reported consultancy/honoraria from Lilly, GlaxoSmithKline, Pfizer, Roche, Boehringer Ingelheim. The other authors have declared no potential conflicts of interest.

references